Bristol-Myers Squibb Company (BMY) PB Ratio: 5.69
Is Bristol-Myers Squibb Company’s P/B ratio high or low?
Bristol-Myers Squibb Company's P/B ratio of 5.69 is 14% above its 5-year average of 4.99, around the middle of its 5-year range (3.23–7.87).
The P/B ratio for Bristol-Myers Squibb Company (BMY) is 5.69. It is below its 12-month average by 2.01% (5.81).
BMY PB Ratio Chart
BMY Average PB Ratio Chart
BMY Current vs Average PB Ratio Chart
BMY PB Ratio Metrics
PB RATIO
5.69
PB RATIO AVG TTM
5.81
PB RATIO AVG 3Y
5.34
PB RATIO AVG 5Y
4.99
PB RATIO AVG 10Y
5.26
PB RATIO AVG 15Y
5.29
PB RATIO AVG 20Y
4.92
CURRENT VS TTM AVG
-2.01%
CURRENT VS 3Y AVG
+6.46%
CURRENT VS 5Y AVG
+14.07%
CURRENT VS 10Y AVG
+8.23%
CURRENT VS 15Y AVG
+7.57%
CURRENT VS 20Y AVG
+15.56%
BMY Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $114.14B | 5.69 | 5.81 | 5.34 | 4.99 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 5.78 | 6.41 | 6.73 | 6.44 |
| CVS Health Corporation (CVS) | $125.16B | 1.62 | 1.29 | 1.17 | 1.37 |
| Medtronic plc (MDT) | $103.04B | 2.11 | 2.44 | 2.28 | 2.41 |
| Danaher Corporation (DHR) | $130.25B | 2.48 | 2.82 | 3.16 | 3.48 |
| Elevance Health Inc. (ELV) | $87.43B | 2.02 | 1.73 | 2.37 | 2.67 |
| Pfizer Inc. (PFE) | $146.36B | 1.63 | 1.63 | 1.71 | 2.35 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 8.52 | 10.30 | 10.61 | 9.88 |
| Cigna Corporation (CI) | $78.25B | 1.85 | 1.87 | 2.04 | 1.94 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 6.49 | 7.47 | 6.02 | 5.35 |
P/B vs. its own history
At 5.69, P/B is richer than usual — richer than 69% of its 20-year range.
20-year low
1.72
median
4.92
20-year high
9.65
Book Value Analysis
P/B Ratio
5.69
Market Price / Book Value per Share
Bristol-Myers Squibb Company PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company PB Ratio FAQ
- What is the P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The P/B ratio for BMY stock is 5.69.
- Is Bristol-Myers Squibb Company's P/B ratio high or low?
- Bristol-Myers Squibb Company's P/B ratio of 5.69 is 14% above its 5-year average of 4.99, around the middle of its 5-year range (3.23–7.87).
- What is the TTM average P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The TTM average P/B ratio for BMY stock is 5.81.
- What is the 3Y average P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The 3Y average P/B ratio for BMY stock is 5.34.
- What is the 5Y average P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The 5Y average P/B ratio for BMY stock is 4.99.
- What is the 10Y average P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The 10Y average P/B ratio for BMY stock is 5.26.
- What is the 15Y average P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The 15Y average P/B ratio for BMY stock is 5.29.
- What is the 20Y average P/B ratio for Bristol-Myers Squibb Company (BMY)?
- The 20Y average P/B ratio for BMY stock is 4.92.
Bristol-Myers Squibb Company PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-10 | 5.69 |
| 2026-06-09 | 5.75 |
| 2026-06-08 | 5.66 |
| 2026-06-05 | 5.83 |
| 2026-06-04 | 5.76 |
| 2026-06-03 | 5.57 |
| 2026-06-02 | 5.55 |
| 2026-06-01 | 5.60 |
| 2026-05-29 | 5.82 |
| 2026-05-28 | 5.80 |
| 2026-05-27 | 5.86 |
| 2026-05-26 | 5.91 |
| 2026-05-22 | 6.05 |
| 2026-05-21 | 6.06 |
| 2026-05-20 | 5.96 |
| 2026-05-19 | 5.94 |
| 2026-05-18 | 5.84 |
| 2026-05-15 | 5.80 |
| 2026-05-14 | 5.78 |
| 2026-05-13 | 5.74 |
| 2026-05-12 | 5.75 |
| 2026-05-11 | 5.67 |
| 2026-05-08 | 5.72 |
| 2026-05-07 | 5.73 |
| 2026-05-06 | 5.76 |
| 2026-05-05 | 5.80 |
| 2026-05-04 | 5.84 |
| 2026-05-01 | 5.93 |
| 2026-04-30 | 6.17 |
| 2026-04-29 | 6.36 |
| 2026-04-28 | 6.44 |
| 2026-04-27 | 6.38 |
| 2026-04-24 | 6.49 |
| 2026-04-23 | 6.52 |
| 2026-04-22 | 6.50 |
| 2026-04-21 | 6.56 |
| 2026-04-20 | 6.53 |
| 2026-04-17 | 6.65 |
| 2026-04-16 | 6.51 |
| 2026-04-15 | 6.40 |
| 2026-04-14 | 6.42 |
| 2026-04-13 | 6.41 |
| 2026-04-10 | 6.48 |
| 2026-04-09 | 6.57 |
| 2026-04-08 | 6.54 |
| 2026-04-07 | 6.37 |
| 2026-04-06 | 6.56 |
| 2026-04-02 | 6.58 |
| 2026-04-01 | 6.82 |
| 2026-03-31 | 6.70 |
| 2026-03-30 | 6.60 |
| 2026-03-27 | 6.47 |
| 2026-03-26 | 6.57 |
| 2026-03-25 | 6.51 |
| 2026-03-24 | 6.34 |
| 2026-03-23 | 6.30 |
| 2026-03-20 | 6.35 |
| 2026-03-19 | 6.42 |
| 2026-03-18 | 6.56 |
| 2026-03-17 | 6.60 |
| 2026-03-16 | 6.60 |
| 2026-03-13 | 6.53 |
| 2026-03-12 | 6.51 |
| 2026-03-11 | 6.63 |
| 2026-03-10 | 6.64 |
| 2026-03-09 | 6.70 |
| 2026-03-06 | 6.66 |
| 2026-03-05 | 6.71 |
| 2026-03-04 | 6.89 |
| 2026-03-03 | 6.76 |
| 2026-03-02 | 6.89 |
| 2026-02-27 | 6.89 |
| 2026-02-26 | 6.75 |
| 2026-02-25 | 6.77 |
| 2026-02-24 | 6.81 |
| 2026-02-23 | 6.77 |
| 2026-02-20 | 6.70 |
| 2026-02-19 | 6.66 |
| 2026-02-18 | 6.60 |
| 2026-02-17 | 6.67 |
| 2026-02-13 | 6.71 |
| 2026-02-12 | 6.61 |
| 2026-02-11 | 6.62 |
| 2026-02-10 | 6.69 |
| 2026-02-09 | 6.68 |
| 2026-02-06 | 6.81 |
| 2026-02-05 | 6.54 |
| 2026-02-04 | 6.33 |
| 2026-02-03 | 6.15 |
| 2026-02-02 | 6.14 |
| 2026-01-30 | 6.05 |
| 2026-01-29 | 5.96 |
| 2026-01-28 | 6.00 |
| 2026-01-27 | 6.10 |
| 2026-01-26 | 6.00 |
| 2026-01-23 | 6.00 |
| 2026-01-22 | 6.04 |
| 2026-01-21 | 5.99 |
| 2026-01-20 | 5.96 |
| 2026-01-16 | 6.07 |
| 2026-01-15 | 6.22 |
| 2026-01-14 | 6.26 |
| 2026-01-13 | 6.14 |
| 2026-01-12 | 6.13 |
| 2026-01-09 | 6.14 |
| 2026-01-08 | 6.14 |
| 2026-01-07 | 6.23 |
| 2026-01-06 | 5.98 |
| 2026-01-05 | 5.83 |
| 2026-01-02 | 5.87 |
| 2025-12-31 | 5.93 |
| 2025-12-30 | 5.96 |
| 2025-12-29 | 5.94 |
| 2025-12-26 | 6.00 |
| 2025-12-24 | 6.01 |
| 2025-12-23 | 5.96 |
| 2025-12-22 | 6.00 |
| 2025-12-19 | 5.95 |
| 2025-12-18 | 5.86 |
| 2025-12-17 | 5.88 |
| 2025-12-16 | 5.96 |
| 2025-12-15 | 5.96 |
| 2025-12-12 | 5.76 |
| 2025-12-11 | 5.62 |
| 2025-12-10 | 5.63 |
| 2025-12-09 | 5.56 |
| 2025-12-08 | 5.68 |
| 2025-12-05 | 5.73 |
| 2025-12-04 | 5.71 |
| 2025-12-03 | 5.60 |
| 2025-12-02 | 5.30 |
| 2025-12-01 | 5.40 |
| 2025-11-28 | 5.40 |
| 2025-11-26 | 5.41 |
| 2025-11-25 | 5.39 |
| 2025-11-24 | 5.25 |
| 2025-11-21 | 5.08 |
| 2025-11-20 | 5.05 |
| 2025-11-19 | 5.03 |
| 2025-11-18 | 5.17 |
| 2025-11-17 | 5.14 |
| 2025-11-14 | 5.12 |
| 2025-11-13 | 5.34 |
| 2025-11-12 | 5.39 |
| 2025-11-11 | 5.35 |
| 2025-11-10 | 5.19 |
| 2025-11-07 | 5.13 |
| 2025-11-06 | 5.12 |
| 2025-11-05 | 5.10 |
| 2025-11-04 | 5.01 |
| 2025-11-03 | 5.06 |
| 2025-10-31 | 5.06 |
| 2025-10-30 | 5.01 |
| 2025-10-29 | 4.98 |
| 2025-10-28 | 5.01 |
| 2025-10-27 | 5.07 |
| 2025-10-24 | 5.12 |
| 2025-10-23 | 5.12 |
| 2025-10-22 | 5.19 |
| 2025-10-21 | 5.21 |
| 2025-10-20 | 5.10 |
| 2025-10-17 | 5.10 |
| 2025-10-16 | 5.07 |
| 2025-10-15 | 5.10 |
| 2025-10-14 | 5.12 |
| 2025-10-13 | 5.09 |
| 2025-10-10 | 5.14 |
| 2025-10-09 | 5.22 |
| 2025-10-08 | 5.21 |
| 2025-10-07 | 5.22 |
| 2025-10-06 | 5.28 |
| 2025-10-03 | 5.31 |
| 2025-10-02 | 5.35 |
| 2025-10-01 | 5.54 |
| 2025-09-30 | 5.27 |
| 2025-09-29 | 5.16 |
| 2025-09-26 | 5.16 |
| 2025-09-25 | 5.07 |
| 2025-09-24 | 5.16 |
| 2025-09-23 | 5.25 |
| 2025-09-22 | 5.26 |
| 2025-09-19 | 5.26 |
| 2025-09-18 | 5.33 |
| 2025-09-17 | 5.39 |
| 2025-09-16 | 5.42 |
| 2025-09-15 | 5.42 |
| 2025-09-12 | 5.40 |
| 2025-09-11 | 5.56 |
| 2025-09-10 | 5.51 |
| 2025-09-09 | 5.52 |
| 2025-09-08 | 5.46 |
| 2025-09-05 | 5.51 |
| 2025-09-04 | 5.46 |
| 2025-09-03 | 5.55 |
| 2025-09-02 | 5.54 |
| 2025-08-29 | 5.51 |
| 2025-08-28 | 5.48 |
| 2025-08-27 | 5.57 |
| 2025-08-26 | 5.52 |
| 2025-08-25 | 5.51 |
| 2025-08-22 | 5.60 |
| 2025-08-21 | 5.66 |
| 2025-08-20 | 5.64 |
| 2025-08-19 | 5.65 |
| 2025-08-18 | 5.63 |
| 2025-08-15 | 5.66 |
| 2025-08-14 | 5.59 |
| 2025-08-13 | 5.59 |
| 2025-08-12 | 5.44 |
| 2025-08-11 | 5.37 |
| 2025-08-08 | 5.37 |
| 2025-08-07 | 5.30 |
| 2025-08-06 | 5.24 |
| 2025-08-05 | 5.36 |
| 2025-08-04 | 5.31 |
| 2025-08-01 | 5.17 |
| 2025-07-31 | 5.06 |
| 2025-07-30 | 5.39 |
| 2025-07-29 | 5.49 |
| 2025-07-28 | 5.57 |
| 2025-07-25 | 5.67 |
| 2025-07-24 | 5.73 |
| 2025-07-23 | 5.74 |
| 2025-07-22 | 5.63 |
| 2025-07-21 | 5.47 |
| 2025-07-18 | 5.55 |
| 2025-07-17 | 5.63 |
| 2025-07-16 | 5.53 |
| 2025-07-15 | 5.44 |
| 2025-07-14 | 5.55 |
| 2025-07-11 | 5.49 |
| 2025-07-10 | 5.68 |
| 2025-07-09 | 5.58 |
| 2025-07-08 | 5.51 |
| 2025-07-07 | 5.45 |
| 2025-07-03 | 5.50 |
| 2025-07-02 | 5.58 |
| 2025-07-01 | 5.57 |
| 2025-06-30 | 5.42 |
| 2025-06-27 | 5.43 |
| 2025-06-26 | 5.46 |
| 2025-06-25 | 5.47 |
| 2025-06-24 | 5.51 |
| 2025-06-23 | 5.50 |
| 2025-06-20 | 5.49 |
| 2025-06-18 | 5.49 |
| 2025-06-17 | 5.53 |
| 2025-06-16 | 5.70 |
| 2025-06-13 | 5.83 |
| 2025-06-12 | 5.94 |
| 2025-06-11 | 5.88 |
| 2025-06-10 | 5.85 |
| 2025-06-09 | 5.74 |
| 2025-06-06 | 5.67 |
| 2025-06-05 | 5.60 |
| 2025-06-04 | 5.62 |
| 2025-06-03 | 5.63 |
| 2025-06-02 | 5.72 |
| 2025-05-30 | 5.66 |
| 2025-05-29 | 5.61 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner